Literature DB >> 1765492

[75 years of Cignolin].

A Scholz1, H Kadner.   

Abstract

Eugen Galewsky (1864-1935), dermatologist in Dresden, introduced 1,8-dihydroxyanthrone (Cignolin, Dithranol) for therapy of psoriasis. He intended to substitute Chrysarobin, a synthetic product, which causes strong discolouring and irritation of skin. In 1916 the firm Farbenfabrik Bayer, Leverkusen, obtained a patent for synthesis of 1.8-dihydroxyanthrone by an inexpensive method. There is a reason to believe that the brother of Eugen Galewsky, the chemist Paul Galewsky, was a co-worker to the Farbenfabrik Bayer and that he recommended his brother Eugen testing Cignolin. Even now Cignolin is still used in the treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1765492

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  2 in total

Review 1.  [Topical treatment of psoriasis: a systematic update].

Authors:  R Aschoff; G Wozel; M Meurer
Journal:  Hautarzt       Date:  2003-02-13       Impact factor: 0.751

2.  [Health economic aspects of psoriasis therapy. Is inpatient topical treatment of plaque-type psoriasis in this age of biologics still appropriate from both medical and economic viewpoints?].

Authors:  M Hahn; T Schulz
Journal:  Hautarzt       Date:  2005-06       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.